EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Children and Young People With First Relapse or Progression of Upfront Metastatic Rhabdomyosarcoma: An Analysis of Clinical Features and Outcomes From the INternational Soft Tissue saRcoma ConsorTium ( INSTRuCT )

Ajla T Wasti, Gianni Bisogno, Beatrice Coppadoro, Ilaria Zanetti, Martin Ebinger, Amadeus T Heinz iD, Henry C Mandeville, Rita Alaggio, Michela Casanova, Sheila E J Terwisscha van Scheltinga, Rick R van Rijn, Veronique Minard-Colin iD und 6 weitere

Cancer Medicine · 2026

DOI: 10.1002/cam4.71524 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2026. Verfasst von Ajla T Wasti und 17 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Cancer Research, Sutton, UK. Hauptthemen laut MEDLINE: Rhabdomyosarcoma, Neoplasm Recurrence, Local. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research Foundation, St Baldrick's Foundation, Seattle Children's Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

We evaluated the survival rate/survivor characteristics following first progression/relapse of metastatic rhabdomyosarcoma (M1 RMS), using pooled European and US collaborative group data from the INternational Soft Tissue saRcoma ConsorTium (INSTRuCT).

Methods

Patients with first diagnosis of M1 RMS aged 0–40 years were identified within the INSTRuCT database (Upfront Cohort; UC). The First Event Cohort (FEC) included UC patients with first event of disease progression/relapse. Clinical features and survival of FEC patients were described.

Results

UC included 1095 eligible M1 RMS patients. 5‐year Overall and Event Free Survival were 32.0% (95% Confidence Interval (CI) 29.2–34.9) and 27.5% (95% CI 24.8–30.2) respectively. Median time to event was 13.9 months (range 1 day‐172.6 months). Among UC patients, 727 with first event of progression/relapse were included in FEC. 3‐year Overall Survival for FEC from first event was 8.0% (95% CI 6.1–10.2). Thirty‐four (4.7%) FEC patients were alive with > 3 years follow up (“disease free”) and 16 (2.2%) with < 3 years follow up. FEC patients alive > 3 years were significantly more likely than deceased FEC patients to have: younger age ( p = 0.0031); no locoregional lymph node involvement ( p = 0.0013); fewer metastatic sites ( p = 0.006); no bone and/or bone marrow disease ( p < 0.001 for each); lower Oberlin scores ( p < 0.0001); time to first event > 18 months ( p < 0.0001). Univariate and multivariable analyses conducted in FEC to investigate factors impacting OS showed that Oberlin score ≥ 2 (Hazard Ratio (HR) 1.295, 95% Confidence Limits (CL) 1.07–1.57, p = 0.0074) and involvement of loco‐regional lymph nodes at diagnosis (HR 1.28, 95% CL 1.08–1.52, p = 0.0053) were associated with worse outcome.

Conclusions

Outcomes following first progression/relapse of M1 RMS are dismal. Survivors had fewer adverse prognostic features at first presentation and later first events. Further work is required to predict survivors of first relapse more reliably.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RhabdomyosarcomaNeoplasm Recurrence, LocalHumansFemaleMaleAdolescentChildChild, PreschoolDisease ProgressionInfantYoung AdultAdultInfant, NewbornPrognosis

Stichwörter der Autor:innen

INSTRuCTmetastaticprognostic factorsprogressionrelapserhabdomyosarcoma

Autor:innen und Institutionen

  • Institute of Cancer Research, Sutton, UK.
  • Department of Women and Children's Health, University of Padova, Padova, Italy.
  • Pediatric Hematology Oncology Division, University Hospital of Padova, Padova, Italy.
  • Department of Pediatric Hematology and Oncology, University Children's Hospital, Tübingen, Germany.
  • Stuttgart Cancer Center, Zentrum für Kinder-, Jugend- und Frauenmedizin (Olgahospital), Pädiatrie 5 (Pädiatrische Onkologie, Hämatologie, Immunologie), Klinikum der Landeshauptstadt Stuttgart, Stuttgart, Germany.
  • Children and Young People's Unit, Royal Marsden Hospital, Sutton, UK.

ORCID-Profile: Amadeus T Heinz, Veronique Minard-Colin, Daniel Orbach, Julia C Chisholm

Förderung

  • Cancer Research Foundation
  • St Baldrick's Foundation
  • Seattle Children's Foundation
  • Stiftung des Fordervereins fur Krebskranke Kinder Tubingen
  • Andrew Mc Donough B+ Foundation
  • Comer Development Board
  • Children's Research Foundation
  • Rally Foundation

Zitieren

APA

Wasti, A. T., Bisogno, G., Coppadoro, B., Zanetti, I., Ebinger, M., Heinz, A. T., Mandeville, H. C., Alaggio, R., Casanova, M., van Scheltinga, S. E. J. T., van Rijn, R. R., Minard-Colin, V., Orbach, D., Collins, N. B., Xue, W., Venkatramani, R., Merks, J. H. M., & Chisholm, J. C. (2026). Children and Young People With First Relapse or Progression of Upfront Metastatic Rhabdomyosarcoma: An Analysis of Clinical Features and Outcomes From the INternational Soft Tissue saRcoma ConsorTium ( INSTRuCT ). Cancer Medicine. https://doi.org/10.1002/cam4.71524

Vancouver

Wasti AT, Bisogno G, Coppadoro B, Zanetti I, Ebinger M, Heinz AT, et al. Children and Young People With First Relapse or Progression of Upfront Metastatic Rhabdomyosarcoma: An Analysis of Clinical Features and Outcomes From the INternational Soft Tissue saRcoma ConsorTium ( INSTRuCT ). Cancer Medicine. 2026. doi:10.1002/cam4.71524

BibTeX
@article{Wasti2026,
  author = {Wasti, Ajla T and Bisogno, Gianni and Coppadoro, Beatrice and Zanetti, Ilaria and Ebinger, Martin and Heinz, Amadeus T and Mandeville, Henry C and Alaggio, Rita and Casanova, Michela and van Scheltinga, Sheila E J Terwisscha and van Rijn, Rick R and Minard-Colin, Veronique and Orbach, Daniel and Collins, Natalie B and Xue, Wei and Venkatramani, Rajkumar and Merks, Johannes H M and Chisholm, Julia C},
  title = {Children and Young People With First Relapse or Progression of Upfront Metastatic Rhabdomyosarcoma: An Analysis of Clinical Features and Outcomes From the INternational Soft Tissue saRcoma ConsorTium ( INSTRuCT )},
  journal = {Cancer Medicine},
  year = {2026},
  doi = {10.1002/cam4.71524}
}
Kostenlos starten →